Chris Bunge
Hedge fund analyst, long/short equity

Cancer Genetics: Major Upside Through Proprietary Tests

Cancer Genetics, Inc. (NASDAQ:CGIX) just came public on April 10, 2013 and raised roughly $62 million through two stock offerings. The company's primary objective is to be a leader in development and commercialization of proprietary genomic tests and services. Given their recent equity offerings, the company is now in a great position to implement their growth strategy. Management has set reasonable growth targets for their business, which could generate substantial revenue growth over the next several years, I believe revenues could grow from the current $7M FY2013 to over $50M by FY2015 and earnings could approach $0.90 to $1.00. I believe the stock could approach $30 by sometime in 2015.

Alan Mertz, president of the American Clinical Laboratory...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details